Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Texas was posted on July 2, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Custom Synthesize Antibody - Drug Conjugates

Closed
739-SL3800457State & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
New
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposal issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an unrestricted, IDIQ contract focused on Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC). The scope of work includes the purchase and storage of VAC, the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract features a ceiling price of 800 million dollars and a long-term performance horizon, consisting of five one-year ordering periods for VAC and direct purchases starting December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The contractor is required to produce VAC with a minimum capacity of 1.0 million doses and maintain storage on their premises under strict quality control and temperature monitoring standards. Due to the nature of the material, live FMDV is classified as a Tier 1 Select Agent, requiring specific authorization from the CDC/APHIS and adherence to rigorous shipping and security restrictions. Award will be based on the most advantageous offer, evaluating technical capability, past performance, and price, with technical and past performance factors weighted equally. Proposals must be submitted electronically in four separate volumes by November 10, 2026.
Mrpbs Minneapolis Mn

POSTED

2 days ago

DEADLINE

in 13 days
NAICS: 325414
DIBBS
JAPANESE ENCEPHALIT
Solicitation # SPE2DP-26-R-0001
Solicitation SPE2DP-26-R-0001 is a sole source, firm-fixed price, indefinite delivery, indefinite quantity contract issued by the Defense Logistics Agency for the procurement of Japanese Encephalitis Virus Vaccine, Purified, Inactivated, in single-dose prefilled syringes. The contract has an eighteen month base term with estimated quantities ranging from a minimum of 277,760 to a maximum of 394,240 units. All products must be FDA approved, serialized according to the Drug Supply Chain Security Act, and manufactured in accordance with Medical Procurement Item Description Number 5. Deliveries are designated as FOB Destination to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, and must be completed within 120 days after the date of order. The successful offeror must demonstrate FDA approval or provide a manufacturer commitment letter ensuring supply availability and fixed pricing for the life of the contract. Proposals must be submitted electronically via the DLA Internet Bid Board System by November 6, 2026. Strict adherence to Medical Marking Standard No. 1D is required, specifically regarding cold chain storage between 2 and 8 degrees Celsius and detailed waterproof marking for exterior containers. Contract administration, including payment requests and receiving reports, will be managed through the Wide Area Workflow system. Award will be based on the most advantageous offer considering price, FDA approval, and agreement to all solicitation terms.
Defense Logistics Agency

POSTED

23 days ago

DEADLINE

in 8 days

AI Contract Overview

Show more

The Texas Tech University Health Sciences Center is soliciting proposals for the custom synthesis of Antibody-Drug Conjugates targeting the c-MYC oncogene, with services defined in Section 5.4 of the solicitation. The contract, identified as RFP 739-SL3800457, is open for submission until May 26, 2026, and is issued under the NAICS code 325414 for pharmaceutical and biological product manufacturing. Proposals must include a signed Execution of Offer, a HUB Subcontracting Plan if applicable, an Addenda Checklist, and Vendor Information forms, all submitted either electronically via the TechBid portal or as a bundled printed copy with a USB drive. The evaluation is based on a best value trade-off approach, with technical specifications accounting for 50 percent of the score, pricing for 30 percent, and experience and reputation for 20 percent. Award will not be based solely on lowest cost, with emphasis placed on quality, long-term value, and conformity to TTUHSC’s specifications, including conjugation chemistry, DAR optimization, and purification to achieve high monomeric purity. Deliverables include a fully characterized ADC product with a Certificate of Analysis and a Final Project Report, delivered in three phases: feasibility, pilot synthesis, and scale-up, with title and risk of loss transferring only upon physical receipt at TTUHSC’s Lubbock, Texas facility. All work must comply with federal, state, and local laws, including OSHA standards, Texas Hazard Communication Act requirements for MSDS submissions, and export controls under ITAR and EAR. Contractors must adhere to TX-RAMP cybersecurity standards and avoid engagement with foreign adversaries. Intellectual property developed under the contract is considered a work made for hire, fully assigned to TTUHSC. Key personnel identified in the proposal require approval and cannot be substituted without written consent. The contract mandates compliance with Texas ethics reporting for agreements valued at $1 million or more via Form 1295 and requires affirmation of child support compliance. Packaging and marking requirements are limited to inclusion of the purchase order number and shipping details on all documentation and shipments, with no military standards applied. Payment terms are Net 30 days, with invoices directed to the TTUHSC Purchasing Office in Lubbock. No formal contract type is designated, but pricing structure implies a fixed-price arrangement. There are no options, extensions, or modification clauses, and no CAGE or UEI

General Info

TTUHSC seeks proposals for custom synthesis of antibody-drug conjugates, deadline May 26, 2026.

Agency

Texas Tech University Health Sciences Center

Place of Performance

TX, USA

Set-Aside

NONE

Documents

1

RFP 739-SL3800457 Custom Synthesize Antibody-Drug Conjugates

PDF, High priority: read this firstrfp
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Response Deadline

Deadline has passed

Posted

Solicitation

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyTexas Tech University Health Sciences Center
Contacts1 person available
OfficeTX, USA
Organization / Agency
Texas Tech University Health Sciences Center
Office AddressTX, USA

Full Description

Show more
The Texas Tech University Health Sciences Center (“TTUHSC”), a part of the Texas Tech University System, seeks proposals from qualified firms for Custom Synthesize Antibody-Drug Conjugates (the “Services”). The Services are more specifically described in Section 5.4 entitled Service Specifications.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS